Pregnancy-related issues from the perspective of patients with inflammatory rheumatic diseases – Results from a survey of the members of the National Association for Inflammatory Rheumatic Diseases
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Atsuko Murashima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Maternal-Fetal, Neonatal and Reproductive Medicine/Drug Information Institute in Pregnancy, National Center for Child Health and Developmen…. Hauptthemen laut MEDLINE: Rheumatic Diseases, Pregnancy Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to clarify the issues related to pregnancy in patients with inflammatory rheumatic diseases (RDs) and to provide useful information for developing medical services from patients’ perspectives.
Methods
A survey involving approximately 5000 members of the Patients Association for Collagen Vascular Diseases Japan was conducted using a questionnaire that was sent and returned by mail. The questionnaire items included age at the time of the survey, types of RDs, association of RDs with pregnancy/childbirth outcomes, and pregnancy-related supports and hindrances.
Results
We received 491 completed questionnaires. The most common RD was systemic lupus erythematosus (n = 309). Approximately 60% of participants had a history of childbirth. Approximately 60% of participants had previously experienced pregnancy-related challenges due to RDs. These included concerns about the influence of drugs on babies, genetic transmission, and active disease. Patients with active disease at the time of conception were more likely to experience disease exacerbation during pregnancy, but this did not correlate with whether the pregnancy was planned.
Conclusion
This study revealed that many patients with RDs experienced pregnancy-related challenges and needed appropriate support based on appropriate information. The findings here should help rheumatologists, healthcare providers, and public agencies provide counselling and information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Maternal-Fetal, Neonatal and Reproductive Medicine/Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.
- Division of Maternal Medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
- Patients Association for Collagen Vascular Diseases Japan, Tokyo, Japan.
- Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.
- Department of Biostatistics M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Kayoko Kaneko
Zitieren
APA
Murashima, A., Kaneko, K., Oguro, H., Mori, Y., Goto, M., Mishima, S., Anzai, T., & Takahashi, K. (2024). Pregnancy-related issues from the perspective of patients with inflammatory rheumatic diseases – Results from a survey of the members of the National Association for Inflammatory Rheumatic Diseases. Modern Rheumatology. https://doi.org/10.1093/mr/roae017
Vancouver
Murashima A, Kaneko K, Oguro H, Mori Y, Goto M, Mishima S, et al. Pregnancy-related issues from the perspective of patients with inflammatory rheumatic diseases – Results from a survey of the members of the National Association for Inflammatory Rheumatic Diseases. Modern Rheumatology. 2024. doi:10.1093/mr/roae017
BibTeX
@article{Murashima2024,
author = {Murashima, Atsuko and Kaneko, Kayoko and Oguro, Hiroshi and Mori, Yukiko and Goto, Mikako and Mishima, Shuko and Anzai, Tatsuhiko and Takahashi, Kunihiko},
title = {Pregnancy-related issues from the perspective of patients with inflammatory rheumatic diseases – Results from a survey of the members of the National Association for Inflammatory Rheumatic Diseases},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae017}
}
EUVIMED